NEWS CENTER

09

2024-05

Nature Communications| Yang Liping's team and CHIGENOVO published the latest research results on gene therapy for crystalline retinal degeneration based on gene editing technology

Nature Communications| Yang Liping's team and CHIGENOVO published the latest research results on gene therapy for crystalline retinal degeneration based on gene editing technology

2024-05-09

Nature Communications| Yang Liping's team and CHIGENOVO published the latest research results on gene therapy for crystalline retinal degeneration based on gene editing technology

25

2024-04

Signal Transduction and Targeted Therapy| Yang Liping's team and CHIGENOVO published the results of the world's first clinical trial of gene replacement therapy for crystalline retinal degeneration

Signal Transduction and Targeted Therapy| Yang Liping's team and CHIGENOVO published the results of the world's first clinical trial of gene replacement therapy for crystalline retinal degeneration

2024-04-25

Signal Transduction and Targeted Therapy| Yang Liping's team and CHIGENOVO published the results of the world's first clinical trial of gene replacement therapy for crystalline retinal degeneration
< 1 >
Medium cause

CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.

HUATAO GROUP

Contact us

Telephone:400-6006223   010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing

WeChat subscription account

Medium cause

Powered by www.300.cn | SEO

Business License